NASD · Healthcare · Biotechnology · USA
Spyre Therapeutics Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
Spyre Therapeutics is a clinical-stage biotechnology company developing extended half-life antibodies and antibody combinations targeting inflammatory pathways for inflammatory bowel disease and rheumatic diseases. The company's pipeline includes monotherapy and pairwise combination candidates designed for quarterly or twice-annual subcutaneous dosing, with clinical trials evaluating treatments in ulcerative colitis and rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Spyre Therapeutics Inc stock.
Not valued: We cannot value this company yet.
17 more funds hold it; the full list is part of the paid plan.
135 more in this industry show a wider margin of safety.
We do not publish a verdict on SYRE yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.
We do not publish one (as of the 2026-10-19 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.